|

PEEL-224 Clinical Trials

3 actively recruiting trials across 3 locations

Pipeline

Phase 1: 1Phase 1/2: 2

Top Sponsors

  • Theodore Laetsch1
  • Peel Therapeutics Inc1
  • David S Shulman, MD1

Indications

  • Cancer3
  • Refractory Sarcoma1
  • Relapsed Rhabdomyosarcoma1
  • Relapsed Solid Tumors1
  • Desmoplastic Small Round Cell Tumor1

Scottsdale, Arizona1 trial

A Study to Evaluate PEEL-224 in Patients With Advanced Solid Tumors

HonorHealth Research Institiute

Phase 1

Boston, Massachusetts1 trial

Phase 1/2 Trial to Evaluate the Safety and Efficacy of PEEL-224 in Combination With Vincristine and Temozolomide in Adolescents and Young Adults With Relapsed or Refractory Sarcomas

Boston Children's Hospital

Phase 1/2

Philadelphia, Pennsylvania1 trial

PEEL-224, Vincristine and Temozolomide in Pediatric Solid Tumors

Children's Hospital of Philadelphia

Phase 1/2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.